Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
Pharvaris (PHVS) Stock Price & Analysis
68 Followers
PHVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.00 - $33.00
Previous Close$17.4
Volume35.62K
Average Volume (3M)61.25K
Market Cap
$936.41M
Enterprise Value$510.52M
Total Cash (Recent Filing)€391.23M
Total Debt (Recent Filing)€238.91K
Price to Earnings (P/E)―
Beta-1.13
Next Earnings
Apr 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.56
Shares Outstanding52,290,212
10 Day Avg. Volume115,364
30 Day Avg. Volume61,251
Standard Deviation0.74
R-Squared0.04
Alpha0.11
Financial Highlights & Ratios
Price to Book (P/B)2.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$37.00Price Target Upside112.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Pharvaris News
PremiumCompany Announcements
Pharvaris Shareholders Approve Key Resolutions
PremiumCompany Announcements
Pharvaris Schedules 2024 Shareholder Meeting
PremiumCompany Announcements
Pharvaris Showcases Promising HAE Treatment DataBulls Say, Bears Say
Bulls Say
Clinical Trial SuccessDeucrictibant led to an impressive 85% placebo-adjusted reduction in HAE attacks which is the best data for an oral prophylactic and on par with injectable options.
Efficacy And Market PotentialDeucrictibant continues to look like the best oral treatment for HAE attacks based on recently published and presented data.
Market PositionPharvaris holds a strong position in the HAE landscape with a differentiated mechanism and is the only company with an oral option for both HAE prophylaxis and acute treatment.
Bears Say
Clinical Trial RiskPHVS did not measure PGI-C in its Phase 2, which introduces some risk to RAPIDe-3.
Data IntegrityThere are some holes in the data that leave the door open for deucrictibant, which compares favorably to sebetralstat.
Drug Efficacy38-41% of sebetralstat patients needed two doses to work, and 44-52% of patients did not resolve their attack in 24 hours.
---
Ownership Overview
0.00%
Insiders
7.94% Mutual Funds
66.51% Other Institutional Investors
25.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $15.00 and its highest was $33.00 in the past 12 months.
What is Pharvaris’s market cap?
Currently, no data Available
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Apr 24, 2025 which is in 269 days.
How were Pharvaris’s earnings last quarter?
Currently, no data Available
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharvaris have?
Pharvaris has 53,816,708 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharvaris?
Among the largest hedge funds holding Pharvaris’s share is Viking Global Investors LP. It holds Pharvaris’s shares valued at 84M.
---
Pharvaris Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.00 (112.64% Upside)
$37.00 (112.64% Upside)
Hedge Fund Trend
Increased
By 145.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.75%
12-Months-Change
Fundamentals
Return on Equity
-43.59%
Trailing 12-Months
Asset Growth
153.96%
Trailing 12-Months
Company Description
Pharvaris
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
---
PHVS Stock 12 Month Forecast
Average Price Target
$37.00
▲(112.64% Upside)
Technical Analysis
Best Analysts Covering PHVS
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+63.73%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +63.73% per trade.
---